Abstract 52P
Background
Chimeric antigen receptor T cells (CAR Ts) have shown limited efficacy in solid tumors due to poor penetration, constrained activity, and early exhaustion into the immunosuppressive tumor microenvironment (TME). While stimulatory cytokines can counteract immune suppression, their systemic administration entails risk of toxicities and counter-regulatory responses.
Methods
Here, we leveraged a population of tumor-associated TIE2 expressing macrophages (TEMs) to specifically release interferon-a (IFN) and/or orthogonal interleukin-2 (oIL2) in the TME through a hematopoietic stem cell-based gene therapy to broadly reprogram it toward immune activation. To investigate whether TME reprogramming could favor CAR-T function in hostile conditions, we took advantage of immunocompetent mice orthotopically challenged with a novel high-grade glioma (HGG) model (mGB2), faithfully recapitulating the human disease. We generated CAR Ts, either bearing an orthogonal IL-2 receptor or not, by optimizing a high-efficiency lentiviral-based transduction protocol of murine T cells.
Results
Targeted cytokine delivery rescued CAR Ts functionality against the clinically relevant antigen B7H3 in the mGB2 model which was refractory to CAR Ts alone. Immunophenotypic and transcriptomic analyses at single-cell resolution showed inhibition of CAR-T premature terminal exhaustion and induction of effector/memory states featuring activation of signaling pathways and transcriptional networks putatively boosting anti-tumor activity, resulting in tumor growth inhibition and survival prolongation. Importantly, IFN, especially when combined with private oIL2 signaling to CAR Ts, also engaged an endogenous T cell response spreading to tumor-associated antigens beyond B7H3. This accounted for rejection of B7H3KO mGB2 rechallenge in mice that cleared the primary tumor.
Conclusions
Overall, the rescued CAR and endogenous T cell function delayed HGG growth and prolonged mice survival, suggesting that the combination of the above two gene and cell therapies, which are already under clinical testing as monotherapies, could achieve synergistic effects also in HGG patients.
Legal entity responsible for the study
The authors.
Funding
Fondazione AIRC per la Ricerca sul Cancro; Louis-Jeantet Foundation through the 2019 Jeantet-Collen Prize for Translational Medicine.
Disclosure
B. Gentner, L. Naldini: Financial Interests, Personal, Ownership Interest: Genenta science. All other authors have declared no conflicts of interest.
Resources from the same session
185P - Characterizing the metabolic reprogramming of mutant ß-catenin in hepatocellular carcinoma
Presenter: Nathalie Wong
Session: Poster Display session
186P - Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
Presenter: BIN XIE
Session: Poster Display session
187P - Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
Presenter: Xiaoting Zhao
Session: Poster Display session
Resources:
Abstract
188P - Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area
Presenter: Zuyin li
Session: Poster Display session
189P - Image-guided labeling of live cells in tertiary lymphoid structures for single-cell transcriptomics
Presenter: Mengrui Cao
Session: Poster Display session
190P - Ex vivo modeling of precision immuno-oncology responses in lung cancer
Presenter: Bassel Alsaed
Session: Poster Display session
191P - Patient-derived 3D-bioprinted tumours as a relevant and innovative tool for immunotherapeutic testing.
Presenter: Kamila Pawlicka
Session: Poster Display session
192P - A new neuroendocrine model and in vitro effect of melatonin and serotonin on the PD-L1 ligand and its immunomodulatory action
Presenter: Dulce Caraveo Gutiérrez
Session: Poster Display session
193P - Humanized mice applying CD47; Prkcd; IL2rg triple KO mice exhibit enhanced human immune cell engraftment and reduced GvHD symptoms
Presenter: Seung-Ho Heo
Session: Poster Display session
194P - The impact of BTK inhibitors on ?d T cell fitness: Lesson for immunotherapy
Presenter: Adam Michalski
Session: Poster Display session